Immunate

Human Coagulation Factor VIII and Human Von Willebrand Factor, the active ingredient in Immunate, is a hemostatic agent presented as a biologic for intravenous use. It replaces deficient clotting factors to treat hemophilia A and von Willebrand disease in patients requiring factor replacement therapy.

GNH USA supplies Immunate as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Immunate acts on the intrinsic coagulation pathway and platelet adhesion mechanisms to manage inherited bleeding disorders.

Hemophilia A: restores deficient factor VIII activity to achieve effective clot formation. Von Willebrand disease: provides von Willebrand factor to improve platelet adhesion and stabilize factor VIII. Surgical or procedural bleeding in affected patients: supplies necessary clotting factors to attain hemostasis during invasive procedures.

Immunate may be associated with infusion-related and immunologic reactions.

Common Side Effects: - Mild fever or chills during or after infusion - Headache or dizziness - Nausea or vomiting - Arthralgia or muscle aches - Transient hypotension - Local site erythema or swelling

Serious or Rare Side Effects: - Anaphylactic or severe allergic reaction - Development of inhibitory antibodies against factor VIII or VWF - Thromboembolic events (deep vein thrombosis, pulmonary embolism) - Renal impairment or hemolysis - Severe bleeding due to inadequate factor activity - Disseminated intravascular coagulation (rare)

Prior to administration, clinicians should assess patient history and monitor for specific risks.

Monitor for inhibitor development: test for anti‑factor VIII antibodies regularly. Assess for allergic reactions: observe during initial infusion for signs of hypersensitivity. Evaluate bleeding risk: ensure appropriate dosing based on severity of hemophilia or VWD. Use caution in cardiovascular disease: avoid excessive pro‑coagulant activity. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Immunate can interact with other agents that affect coagulation or immune response.

Major Interactions (Avoid): - Concurrent use of other factor VIII concentrates may increase inhibitor formation risk. - Co‑administration with anticoagulants (e.g., warfarin, direct oral anticoagulants) may diminish hemostatic efficacy. - Use with desmopressin in VWD patients may lead to excessive VWF levels.

Moderate Interactions (Monitor Closely): - Immunosuppressive therapy may alter antibody response to the product. - Concomitant use of high‑dose steroids could mask infusion reactions. - Certain antibiotics (e.g., beta‑lactams) may increase risk of hypersensitivity; monitor closely.